重组人组织型纤溶酶原激活剂治疗危重脑梗死的疗效

目的探讨重组人组织型纤溶酶原激活剂治疗危重脑梗死患者的临床疗效。方法随机选取我院收治的脑梗死患者210例,溶栓组97例,静脉给予重组人组织型纤溶酶原激活剂(rt-PA)0.9 mg/kg,最大剂量50 mg,10%剂量静推,剩余剂量加入氯化钠生理盐水250 mL中1.5 h滴完。对照组113例进行常规保守治疗,给予肠溶阿司匹林片、他汀类等治疗。结果 rt-PA溶栓组治疗前后各阶段的NIHSS评分比较差异均有统计学意义(P<0.01);溶栓组和对照组治疗后90 d,预后Barthel指数比较差异有统计学意义(P<0.05)。溶栓组临床疗效优于对照组,两组比较差异有统计学意义(P<0.05)。结论重组人组织型纤溶酶原激活剂溶栓治疗能提高脑梗死患者术后生活质量,明显改善患者的神经功能,恢复其生活能力,提高生活质量。

Curative effect of recombinant human tissue type plasminogen activator on patients with severe cerebral infarction

Objective To investigate the effect of recombinant human tissue plasminogen activator on patients with severe cerebral infarction.Methods 210 cases of cerebral infarction patients were randomly selected.Thrombolysis group(n = 97) was given recombinant tissue plasminogen activator(rt-PA) 0.9 mg / kg,the maximum dose of 50 mg,10% intravenously,the residual dose of sodium chloride w as added normal saline 250 mL 90 min drop.The control group(n = 113) received conventional conservative treatment,such as aspirin,a statin therapy.Results The NIHSS scores of thrombolysis group had significant difference at different periods before and after treatment(P < 0.01);the prognosis Barthel index of thrombolysis group and control group had significant difference after treaed for 90 days(P < 0.05).Therapeutic effect of thrombolysis group w as better than that of control group(P < 0.05).Conclusion Recombinant human tissue plasminogen activator treatment has great influence on the quality of life in patients with cerebral infarction,it can significantly improve the patients' neurological recovery,and improve the life quality of patients.